But there’s a big problem — DeepSeek does not appear to have conducted any predeployment safety testing. There is no mention ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

“Bill Gates was bitching about us changing JS all the time,” Eich later recalled of the fall of 1996. Microsoft created its ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Trevor Lawrence has played plenty of meaningful games in December. And not just at Clemson. The Jaguars quarterback was part ...